Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Cell Medica
Cell Medica
Activities:
Research & Development
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Overcoming CMC challenges in cell and gene therapy: part I
Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC...
Resolving capping issues in tablet manufacturing
Natoli explores the various causes of capping and the methods to prevent it
Effective ways to optimise heat exchangers
Heat exchangers are used within a wide range of process industries as a way to transfer heat between two fluid streams across a medium in an energy conservative way
Transforming healthcare with patient centricity
In this opinion article, John Kytariolos, Head of Clinical and Scientific Affairs at Adragos Pharma, discusses patient-centric dosage forms, their properties and the impact...
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Cell Medica appoints new CEO
Design & Build
Cell and Gene Therapy Catapult opens manufacturing centre
More than £60 million of UK government investment is being used to develop the new centre, which aims to accelerate growth of the industry in the UK
Recruitment
New CFO to lead Cell Medica financing
Research & Development
Cell Medica appoints CSO to accelerate R&D for CAR and TCR programmes
Media
Cell Medica acquires WT1 cancer immunotherapy from CGT Catapult
The acquisition transfers rights for WT1-TCR cell therapy from CGT Catapult to Cell Medica, also establishing development and manufacturing collaboration
Research & Development
Cell Medica and UCL to develop T cell receptor cancer products
Cell Medica gains an exclusive worldwide option and licensing agreement for these technologies
Pharmaceutical
Cell Medica begins commercial production at cell therapy facility in Germany
The first product has been manufactured and delivered to the patient
Subscribe now